{"protocolSection": {"identificationModule": {"nctId": "NCT03447990", "orgStudyIdInfo": {"id": "MYK-491-003"}, "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491", "officialTitle": "Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction"}, "statusModule": {"statusVerifiedDate": "2023-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-02-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-10-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-02-14", "studyFirstSubmitQcDate": "2018-02-21", "studyFirstPostDateStruct": {"date": "2018-02-27", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-10-21", "resultsFirstSubmitQcDate": "2023-01-09", "resultsFirstPostDateStruct": {"date": "2023-02-02", "type": "ACTUAL"}, "dispFirstSubmitDate": "2020-10-22", "dispFirstSubmitQcDate": "2023-01-09", "dispFirstPostDateStruct": {"date": "2023-02-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-01-09", "lastUpdatePostDateStruct": {"date": "2023-02-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure."}, "conditionsModule": {"conditions": ["Heart Failure With Reduced Ejection Fraction", "Dilated Cardiomyopathy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "This is a a two part study. The first part is a randomized, crossover, double-blind, placebo-controlled, two cohort, sequential ascending single dose study. All patients will receive placebo and active doses of MYK-491.\n\nThe second part is a randomized, parallel, double-blind, placebo-controlled, sequential ascending multiple dose study. All patients will receive placebo and/or active doses of MYK-491.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 52, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Part 1/SAD and Part 2/MAD - drug", "type": "OTHER", "description": "Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo\n\nPart 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo", "interventionNames": ["Drug: MYK-491"]}, {"label": "Part 1/SAD and Part 2/MAD - placebo", "type": "OTHER", "description": "Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo\n\nPart 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "MYK-491", "description": "Single Ascending Dose and Multiple Ascending Dose of MYK-491", "armGroupLabels": ["Part 1/SAD and Part 2/MAD - drug"]}, {"type": "DRUG", "name": "Placebo", "description": "Single Ascending Dose and Multiple Ascending Dose of placebo", "armGroupLabels": ["Part 1/SAD and Part 2/MAD - placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)", "description": "Number of participants with any grade of treatment-emergent adverse events (TEAEs) and any grade of serious adverse events (SAEs).", "timeFrame": "From first dose to 30 days post last dose (Up to 2 months)"}, {"measure": "Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts", "description": "Number of participants with change from baseline in ECGs QTcF, PR, and QRS intervals. Baseline is defined as the last non-missing value prior to the corresponding period.", "timeFrame": "Baseline, day 1-16, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose"}, {"measure": "Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - MAD Cohorts", "description": "Number of participants with change from baseline in ECGs QTcF, PR, and QRS intervals. Baseline is defined as the last non-missing value prior to first randomized dose.", "timeFrame": "Baseline, Day 1-16, 2 hours pre-dose and at 7-, 24-, and 48-hours post final dose"}, {"measure": "Mean Change From Baseline in Vital Signs Part 1 - SAD Cohorts", "description": "Mean change from baseline in supine systolic blood pressure (SBP) and supine diastolic blood pressure (DBP) vital signs. Baseline is defined as the last non-missing value prior to the corresponding period.", "timeFrame": "Baseline and at 6-hours post-dose"}, {"measure": "Mean Change From Baseline in Vital Signs Part 1 - MAD Cohorts", "description": "Mean change from baseline in supine systolic blood pressure (SBP) and supine diastolic blood pressure (DBP) vital signs. Baseline is defined as the last non-missing value prior to first randomized dose", "timeFrame": "Baseline and at 6-hours post-dose"}, {"measure": "Mean Change From Baseline in Vital Signs Part 2 - SAD Cohorts", "description": "Mean change from baseline in heart rate (HR) vital signs. Baseline is defined as the last non-missing value prior to the corresponding period.", "timeFrame": "Baseline and at 6-hours post-dose"}, {"measure": "Mean Change From Baseline in Vital Signs Part 2 - MAD Cohorts", "description": "Mean change from baseline in heart rate (HR) vital signs. Baseline is defined as the last non-missing value prior to first randomized dose", "timeFrame": "Baseline and at 6-hours post-dose"}, {"measure": "Number of Participants With a Troponin I Increase - SAD Cohorts", "description": "Number of participants with a troponin increase is defined as when one of the following conditions was met (1) if the participant's troponin I value was normal prior to dosing (\u22640.03 ng/mL), an elevated level on at least one measurement after start of dosing \\>2\u00d7ULN for the specific assay (\\>0.06 ng/mL) through Day 16. (2) If the participant's troponin I value was above the ULN for the specific assay prior to dosing, an increase \\>0.03 ng/mL compared to baseline on at least one measurement after start of dosing through Day 16.", "timeFrame": "Baseline, day 1-3, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose"}, {"measure": "Number of Participants With a Troponin I Increase - MAD Cohorts", "description": "Number of participants with a troponin increase is defined as when one of the following conditions was met (1) if the participant's troponin I value was normal prior to dosing (\u22640.03 ng/mL), an elevated level on at least one measurement after start of dosing \\>2\u00d7ULN for the specific assay (\\>0.06 ng/mL) through Day 16. (2) If the participant's troponin I value was above the ULN for the specific assay prior to dosing, an increase \\>0.03 ng/mL compared to baseline on at least one measurement after start of dosing through Day 16.", "timeFrame": "Baseline, pre-dose and 7hr post dose on treatment day 1, day 2, day 5 and pre-dose and at 7-, 24-, and 48-hours post final dose"}, {"measure": "Number of Participants With Clinically Significant Laboratory Abnormalities", "description": "Number of participants with clinically significant laboratory abnormalities.", "timeFrame": "From first dose to 30 days post last dose (Up to 2 months)"}, {"measure": "Number of Participants With Clinically Significant Physical Examinations Abnormalities", "description": "Number of participants with clinically significant physical examinations abnormalities.", "timeFrame": "From first dose to 30 days post last dose (Up to 2 months)"}], "secondaryOutcomes": [{"measure": "Danicamtiv Maximum Observed Plasma Concentration (Cmax)", "description": "Maximum observed plasma concentration (Cmax) for Danicamtiv. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose"}, {"measure": "Danicamtiv Time of Maximum Observed Plasma Concentration (Tmax)", "description": "Time of maximum observed plasma concentration (Tmax) for Danicamtiv.", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose"}, {"measure": "Area Under the Plasma Concentration-Time Curve (AUC)", "description": "Area under the plasma concentration-time curve (AUC) for Danicamtiv including the following time points: (AUC(0-12))=from time 0 to 12 hours; (AUC(0-24))=from time 0 to 24 hours; (AUC(0-48))=from time 0 to 48 hours; (AUClast)=from time 0 up to the last measurable concentration; (AUC(0-\u221e))=from time 0 to infinity. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose"}, {"measure": "Apparent First-order Terminal Elimination Half-life (t1/2)", "description": "Apparent first-order terminal elimination half-life (t1/2).", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose"}, {"measure": "Danicamtiv Accumulation Ratio for Maximum Observed Plasma Concentration AR(Cmax) - MAD Cohorts", "description": "Accumulation ratio for maximum observed plasma concentration AR(Cmax) for Danicamtiv. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose"}, {"measure": "Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours AR(AUC(0-12)) - MAD Cohorts", "description": "Accumulation ratio for area under the plasma concentration-time curve from time 0 to 12 hours AR(AUC(0-12)) for Danicamtiv. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose"}, {"measure": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 1 - SAD Cohorts", "description": "Mean change from baseline in TTE parameter systolic ejection time (SET) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to the corresponding period. Reporting arms are not mutually exclusive", "timeFrame": "Baseline, predose and at 3, 6, 9, and 24 hours post dose"}, {"measure": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 2 - SAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular stroke volume (LVSV) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to the corresponding period. Reporting arms are not mutually exclusive", "timeFrame": "Baseline, predose and at 3, 6, 9, and 24 hours post dose"}, {"measure": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 3 - SAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to the corresponding period. Reporting arms are not mutually exclusive", "timeFrame": "Baseline, predose and at 3, 6, 9, and 24 hours post dose"}, {"measure": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 1 - MAD Cohorts", "description": "Mean change from baseline in TTE parameter systolic ejection time (SET) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to first randomized dose. Reporting arms are not mutually exclusive", "timeFrame": "Baseline, predose, and at 7 hours post dose on day 1,2,3, 4, 7, 9, 10, and 11"}, {"measure": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 2 - MAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular stroke volume (LVSV) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to first randomized dose. Reporting arms are not mutually exclusive", "timeFrame": "Baseline, predose, and at 7 hours post dose on day 1,2,3, 4, 7, 9, 10, and 11"}, {"measure": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 3 - MAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to first randomized dose. Reporting arms are not mutually exclusive", "timeFrame": "Baseline, predose, and at 7 hours post dose on day 1,2,3, 4, 7, 9, 10, and 11"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Has stable chronic heart failure with reduced ejection fraction\n* Has adequate acoustic windows for echocardiography\n\nKey Exclusion Criteria:\n\n* Any significant structural cardiac abnormalities on Screening TTE\n* At Screening, symptomatic hypotension or hypertension or bradycardia.\n* Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, vasodilators \\[e.g., nesiritide\\], diuretics) or routinely scheduled ultrafiltration.\n* Presence of protocol specified laboratory abnormalities at Screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Jacksonville Center for Clinical Research", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Prism Reseach", "city": "Saint Paul", "state": "Minnesota", "zip": "55102", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "St. Louis Heart and Vascular Cardiology", "city": "Saint Louis", "state": "Missouri", "zip": "63136", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Newark Beth Israel Medical Center", "city": "Newark", "state": "New Jersey", "zip": "07112", "country": "United States", "geoPoint": {"lat": 40.73566, "lon": -74.17237}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Ohio State University Medical Center", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Oregon Health & Science University", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "University of Pennsylvania Heart and Vascular Center", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Tennessee Center for Clinical Trials", "city": "Tullahoma", "state": "Tennessee", "zip": "37388", "country": "United States", "geoPoint": {"lat": 35.36202, "lon": -86.20943}}, {"facility": "Hopital Europeen Georges-Pompidou", "city": "Paris", "zip": "75015", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Charite Research Organization", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Groningen UMC", "city": "Groningen", "zip": "9713 GZ", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "D&A Research", "city": "Sneek", "zip": "8601", "country": "Netherlands", "geoPoint": {"lat": 53.03297, "lon": 5.6589}}, {"facility": "Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny z Pododdzialem Intensywnego Nadzoru Kardiologicznego i Pododdzialem Leczenia Zaburzen Rytmu Serca", "city": "Wroc\u0142aw", "zip": "51-124", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Wojewodzki Szpital Specjalistyczny Im M Kopernika", "city": "\u0141\u00f3d\u017a", "zip": "93-513", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Karolinska University Hospital", "city": "Stockholm", "zip": "17164", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Queen Elizabeth University Hospital", "city": "Glasgow", "state": "Scotland", "zip": "G51 4TF", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "SAD Cohort 1", "description": "Participants received 3 double-blinded single ascending doses in random sequence (1 placebo, Danicamtiv 175mg and Danicamtiv 350mg) in Period A, B, and C with intervals between doses ranging from 3 to 14 days. Some participants received a fourth single dose of Danicamtiv ranging between 350mg-550mg in the optional open-label period D"}, {"id": "FG001", "title": "SAD Cohort 2", "description": "Participants received 3 double-blinded single ascending doses in random sequence (1 placebo, Danicamtiv 400mg and Danicamtiv 500mg) in Period A, B, and C with intervals between doses ranging from 3 to 14 days"}, {"id": "FG002", "title": "MAD Cohort 1", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg (fasting) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "FG003", "title": "MAD Cohort 2", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "FG004", "title": "MAD Cohort 3", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "FG005", "title": "MAD Cohort 4", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "FG006", "title": "MAD Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Started = Randomized and treated", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "6"}, {"groupId": "FG006", "numSubjects": "10"}]}, {"type": "Completed Blinded Treatment Period A", "comment": "Blinded treatment period A planned in SAD Cohort 1 and 2", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Completed Blinded Treatment Period B", "comment": "Blinded treatment period B planned in SAD Cohort 1 and 2", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Completed Blinded Treatment Period C", "comment": "Blinded treatment period C planned in SAD Cohort 1 and 2", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Completed Optional Open-Label Treatment Period D", "comment": "Optional open-label treatment period D planned in SAD Cohort 1", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "COMPLETED", "comment": "Completed = completed treatment", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "6"}, {"groupId": "FG006", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SAD Cohort 1", "description": "Participants received 3 double-blinded single ascending doses in random sequence (1 placebo, Danicamtiv 175mg and Danicamtiv 350mg) in Period A, B, and C with intervals between doses ranging from 3 to 14 days. Some participants received a fourth single dose of Danicamtiv ranging between 350mg-550mg in the optional open-label period D"}, {"id": "BG001", "title": "SAD Cohort 2", "description": "Participants received 3 double-blinded single ascending doses in random sequence (1 placebo, Danicamtiv 400mg and Danicamtiv 500mg) in Period A, B, and C with intervals between doses ranging from 3 to 14 days"}, {"id": "BG002", "title": "MAD Cohort 1", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg (fasting) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "BG003", "title": "MAD Cohort 2", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "BG004", "title": "MAD Cohort 3", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "BG005", "title": "MAD Cohort 4", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "BG006", "title": "MAD Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "BG007", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "10"}, {"groupId": "BG007", "value": "52"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.1", "spread": "9.4"}, {"groupId": "BG001", "value": "57.5", "spread": "5.07"}, {"groupId": "BG002", "value": "62.7", "spread": "12.50"}, {"groupId": "BG003", "value": "63.0", "spread": "9.86"}, {"groupId": "BG004", "value": "56.8", "spread": "5.09"}, {"groupId": "BG005", "value": "58.5", "spread": "5.36"}, {"groupId": "BG006", "value": "58.6", "spread": "6.98"}, {"groupId": "BG007", "value": "59.2", "spread": "8.11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "14"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "5"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "38"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "51"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "3"}, {"groupId": "BG007", "value": "16"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "7"}, {"groupId": "BG007", "value": "36"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)", "description": "Number of participants with any grade of treatment-emergent adverse events (TEAEs) and any grade of serious adverse events (SAEs).", "populationDescription": "All treated participants per regimen dosage", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From first dose to 30 days post last dose (Up to 2 months)", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Placebo", "description": "Participants received single dose of Placebo in either period A, B, or C"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "SAD Cohort 2 Placebo", "description": "Participants received single dose of Placebo"}, {"id": "OG009", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG010", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG011", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG012", "title": "MAD Cohort Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "4"}, {"groupId": "OG009", "value": "9"}, {"groupId": "OG010", "value": "15"}, {"groupId": "OG011", "value": "6"}, {"groupId": "OG012", "value": "10"}]}], "classes": [{"title": "TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "7"}, {"groupId": "OG010", "value": "6"}, {"groupId": "OG011", "value": "4"}, {"groupId": "OG012", "value": "4"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "1"}, {"groupId": "OG011", "value": "0"}, {"groupId": "OG012", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts", "description": "Number of participants with change from baseline in ECGs QTcF, PR, and QRS intervals. Baseline is defined as the last non-missing value prior to the corresponding period.", "populationDescription": "All treated participants in SAD Cohorts per regimen dosage", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline, day 1-16, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Placebo", "description": "Participants received single dose of Placebo in either period A, B, or C"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "SAD Cohort 2 Placebo", "description": "Participants received single dose of Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "4"}]}], "classes": [{"title": "Change in QTcF from Baseline > 30msec", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "1"}, {"groupId": "OG008", "value": "2"}]}]}, {"title": "Change in QTcF from Baseline > 60msec", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "1"}]}]}, {"title": "Change in PR from baseline > 25%", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}]}, {"title": "Change in QRS from baseline > 25%", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - MAD Cohorts", "description": "Number of participants with change from baseline in ECGs QTcF, PR, and QRS intervals. Baseline is defined as the last non-missing value prior to first randomized dose.", "populationDescription": "All treated participants in MAD Cohorts per regimen dosage", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline, Day 1-16, 2 hours pre-dose and at 7-, 24-, and 48-hours post final dose", "groups": [{"id": "OG000", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG001", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG002", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG003", "title": "MAD Cohort Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "10"}]}], "classes": [{"title": "Change in QTcF from Baseline > 30msec", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "3"}]}]}, {"title": "Change in QTcF from Baseline > 60msec", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Change in PR from baseline > 25%", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "Change in QRS from baseline > 25%", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "2"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Vital Signs Part 1 - SAD Cohorts", "description": "Mean change from baseline in supine systolic blood pressure (SBP) and supine diastolic blood pressure (DBP) vital signs. Baseline is defined as the last non-missing value prior to the corresponding period.", "populationDescription": "All treated participants in SAD Cohorts per regimen dosage", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and at 6-hours post-dose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Placebo", "description": "Participants received single dose of Placebo in either period A, B, or C"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "SAD Cohort 2 Placebo", "description": "Participants received single dose of Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "4"}]}], "classes": [{"title": "Supine SBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.13", "spread": "12.23"}, {"groupId": "OG001", "value": "-11.38", "spread": "9.90"}, {"groupId": "OG002", "value": "-1.38", "spread": "15.02"}, {"groupId": "OG003", "value": "16.00", "spread": "NA", "comment": "SD was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "-7.00", "spread": "19.80"}, {"groupId": "OG005", "value": "-9.50", "spread": "2.12"}, {"groupId": "OG006", "value": "2.50", "spread": "4.359"}, {"groupId": "OG007", "value": "01.75", "spread": "15.650"}, {"groupId": "OG008", "value": "0.00", "spread": "11.633"}]}]}, {"title": "Supine DBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.50", "spread": "12.14"}, {"groupId": "OG001", "value": "9.50", "spread": "6.44"}, {"groupId": "OG002", "value": "-5.75", "spread": "13.04"}, {"groupId": "OG003", "value": "12.00", "spread": "NA", "comment": "SD was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "-1.00", "spread": "5.66"}, {"groupId": "OG005", "value": "-4.00", "spread": "8.49"}, {"groupId": "OG006", "value": "4.00", "spread": "9.933"}, {"groupId": "OG007", "value": "-2.25", "spread": "17.270"}, {"groupId": "OG008", "value": "-3.00", "spread": "14.674"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Vital Signs Part 1 - MAD Cohorts", "description": "Mean change from baseline in supine systolic blood pressure (SBP) and supine diastolic blood pressure (DBP) vital signs. Baseline is defined as the last non-missing value prior to first randomized dose", "populationDescription": "Pre-specified for data to be collected by combining all treated participants with vital signs measurements in MAD Cohorts per regimen only", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and at 6-hours post-dose", "groups": [{"id": "OG000", "title": "MAD Cohorts Danicamtiv", "description": "MAD cohorts at doses ranging from 50 mg to 100 mg"}, {"id": "OG001", "title": "MAD Cohorts Placebo", "description": "MAD cohorts with participants that received placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"title": "Supine SBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.86", "spread": "7.537"}, {"groupId": "OG001", "value": "-6.33", "spread": "3.215"}]}]}, {"title": "Supine DBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.57", "spread": "7.323"}, {"groupId": "OG001", "value": "-5.67", "spread": "3.055"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Vital Signs Part 2 - SAD Cohorts", "description": "Mean change from baseline in heart rate (HR) vital signs. Baseline is defined as the last non-missing value prior to the corresponding period.", "populationDescription": "All treated participants in SAD Cohorts per regimen dosage", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats/min", "timeFrame": "Baseline and at 6-hours post-dose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Placebo", "description": "Participants received single dose of Placebo in either period A, B, or C"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "SAD Cohort 2 Placebo", "description": "Participants received single dose of Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.13", "spread": "6.20"}, {"groupId": "OG001", "value": "-1.25", "spread": "5.75"}, {"groupId": "OG002", "value": "3.00", "spread": "5.50"}, {"groupId": "OG003", "value": "5.00", "spread": "NA", "comment": "SD was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "5.50", "spread": "0.71"}, {"groupId": "OG005", "value": "-1.50", "spread": "2.12"}, {"groupId": "OG006", "value": "3.75", "spread": "9.743"}, {"groupId": "OG007", "value": "-0.50", "spread": "5.000"}, {"groupId": "OG008", "value": "-6.50", "spread": "13.699"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Vital Signs Part 2 - MAD Cohorts", "description": "Mean change from baseline in heart rate (HR) vital signs. Baseline is defined as the last non-missing value prior to first randomized dose", "populationDescription": "Pre-specified for data to be collected by combining all treated participants with vital signs measurements in MAD Cohorts per regimen only", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats/min", "timeFrame": "Baseline and at 6-hours post-dose", "groups": [{"id": "OG000", "title": "MAD Cohorts Danicamtiv", "description": "MAD cohorts at doses ranging from 50 mg to 100 mg"}, {"id": "OG001", "title": "MAD Cohorts Placebo", "description": "MAD cohorts with participants that received placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.71", "spread": "2.563"}, {"groupId": "OG001", "value": "3.33", "spread": "2.517"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With a Troponin I Increase - SAD Cohorts", "description": "Number of participants with a troponin increase is defined as when one of the following conditions was met (1) if the participant's troponin I value was normal prior to dosing (\u22640.03 ng/mL), an elevated level on at least one measurement after start of dosing \\>2\u00d7ULN for the specific assay (\\>0.06 ng/mL) through Day 16. (2) If the participant's troponin I value was above the ULN for the specific assay prior to dosing, an increase \\>0.03 ng/mL compared to baseline on at least one measurement after start of dosing through Day 16.", "populationDescription": "Pre-specified for data to be collected by combining all treated participants in SAD Cohorts per regimen only", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline, day 1-3, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose", "groups": [{"id": "OG000", "title": "SAD Cohorts Danicamtiv", "description": "SAD cohorts at doses ranging from 175 mg to 550 mg"}, {"id": "OG001", "title": "SAD Cohorts Placebo", "description": "SAD cohorts with participants that received placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With a Troponin I Increase - MAD Cohorts", "description": "Number of participants with a troponin increase is defined as when one of the following conditions was met (1) if the participant's troponin I value was normal prior to dosing (\u22640.03 ng/mL), an elevated level on at least one measurement after start of dosing \\>2\u00d7ULN for the specific assay (\\>0.06 ng/mL) through Day 16. (2) If the participant's troponin I value was above the ULN for the specific assay prior to dosing, an increase \\>0.03 ng/mL compared to baseline on at least one measurement after start of dosing through Day 16.", "populationDescription": "Pre-specified for data to be collected by combining all treated participants in MAD Cohorts per regimen only", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline, pre-dose and 7hr post dose on treatment day 1, day 2, day 5 and pre-dose and at 7-, 24-, and 48-hours post final dose", "groups": [{"id": "OG000", "title": "MAD Cohorts Danicamtiv", "description": "MAD cohorts at doses ranging from 50 mg to 100 mg"}, {"id": "OG001", "title": "MAD Cohorts Placebo", "description": "MAD cohorts with participants that received placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Clinically Significant Laboratory Abnormalities", "description": "Number of participants with clinically significant laboratory abnormalities.", "populationDescription": "Pre-specified for data to be collected by combining all treated participants per SAD and MAD Cohort only", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From first dose to 30 days post last dose (Up to 2 months)", "groups": [{"id": "OG000", "title": "SAD Cohorts", "description": "SAD cohorts Placebo and Danicamtiv at doses ranging from 175 mg to 550 mg"}, {"id": "OG001", "title": "MAD Cohorts", "description": "MAD cohorts Placebo and Danicamtiv doses ranging from 50 mg to 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Clinically Significant Physical Examinations Abnormalities", "description": "Number of participants with clinically significant physical examinations abnormalities.", "populationDescription": "Pre-specified for data to be collected by combining all treated participants per SAD and MAD Cohort only", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From first dose to 30 days post last dose (Up to 2 months)", "groups": [{"id": "OG000", "title": "SAD Cohorts", "description": "SAD cohorts Placebo and Danicamtiv at doses ranging from 175 mg to 550 mg"}, {"id": "OG001", "title": "MAD Cohorts", "description": "MAD cohorts Placebo and Danicamtiv doses ranging from 50 mg to 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Danicamtiv Maximum Observed Plasma Concentration (Cmax)", "description": "Maximum observed plasma concentration (Cmax) for Danicamtiv. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "populationDescription": "All participants that received Danicamtiv with plasma concertation data", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 350mg Period D", "description": "Participants received single dose of Danicamtiv 350mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG009", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG010", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "15"}, {"groupId": "OG010", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1476.63", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 22.72"}, {"groupId": "OG001", "value": "2655.83", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 29.47"}, {"groupId": "OG002", "value": "4420.00", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG003", "value": "3590.00", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "2718.51", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 4.68"}, {"groupId": "OG005", "value": "5263.71", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 9.28"}, {"groupId": "OG006", "value": "5337.58", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 24.65"}, {"groupId": "OG007", "value": "5740.50", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 25.86"}, {"groupId": "OG008", "value": "792.5", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 20.2"}, {"groupId": "OG009", "value": "1174.3", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 19.1"}, {"groupId": "OG010", "value": "1452.8", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 21.9"}]}]}]}, {"type": "SECONDARY", "title": "Danicamtiv Time of Maximum Observed Plasma Concentration (Tmax)", "description": "Time of maximum observed plasma concentration (Tmax) for Danicamtiv.", "populationDescription": "All participants that received Danicamtiv with plasma concertation data", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 350mg Period D", "description": "Participants received single dose of Danicamtiv 350mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG009", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG010", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "15"}, {"groupId": "OG010", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.14", "lowerLimit": "2.0", "upperLimit": "6.3"}, {"groupId": "OG001", "value": "6.18", "lowerLimit": "3.7", "upperLimit": "9.1"}, {"groupId": "OG002", "value": "12.0", "lowerLimit": "12.0", "upperLimit": "12.0"}, {"groupId": "OG003", "value": "4.1", "lowerLimit": "4.1", "upperLimit": "4.1"}, {"groupId": "OG004", "value": "5.74", "lowerLimit": "5.4", "upperLimit": "6.1"}, {"groupId": "OG005", "value": "8.93", "lowerLimit": "7.9", "upperLimit": "9.9"}, {"groupId": "OG006", "value": "9.13", "lowerLimit": "6.0", "upperLimit": "12.2"}, {"groupId": "OG007", "value": "9.08", "lowerLimit": "6.0", "upperLimit": "10.0"}, {"groupId": "OG008", "value": "4.983", "lowerLimit": "3.00", "upperLimit": "9.00"}, {"groupId": "OG009", "value": "4.000", "lowerLimit": "1.00", "upperLimit": "12.05"}, {"groupId": "OG010", "value": "3.500", "lowerLimit": "2.03", "upperLimit": "9.00"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Plasma Concentration-Time Curve (AUC)", "description": "Area under the plasma concentration-time curve (AUC) for Danicamtiv including the following time points: (AUC(0-12))=from time 0 to 12 hours; (AUC(0-24))=from time 0 to 24 hours; (AUC(0-48))=from time 0 to 48 hours; (AUClast)=from time 0 up to the last measurable concentration; (AUC(0-\u221e))=from time 0 to infinity. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "populationDescription": "All participants that received Danicamtiv with plasma concertation data", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hr x ng/mL", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 350mg Period D", "description": "Participants received single dose of Danicamtiv 350mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG009", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG010", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "15"}, {"groupId": "OG010", "value": "6"}]}], "classes": [{"title": "(AUC(0-12))", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "15"}, {"groupId": "OG010", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG008", "value": "7169.245", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 18.6"}, {"groupId": "OG009", "value": "10310.794", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 20.4"}, {"groupId": "OG010", "value": "12728.956", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 16.8"}]}]}, {"title": "(AUC(0-24))", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26411.97", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 21.31"}, {"groupId": "OG001", "value": "48981.93", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 27.15"}, {"groupId": "OG002", "value": "79175.02", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG003", "value": "70138.66", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "54004.82", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 4.58"}, {"groupId": "OG005", "value": "97640.90", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 10.10"}, {"groupId": "OG006", "value": "86110.51", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 17.56"}, {"groupId": "OG007", "value": "97656.38", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 15.82"}]}]}, {"title": "(AUC(0-48))", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "40068.47", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 20.91"}, {"groupId": "OG001", "value": "76497.78", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 27.81"}, {"groupId": "OG002", "value": "143543.52", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG003", "value": "89356.54", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "89341.77", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 2.23"}, {"groupId": "OG005", "value": "159193.47", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 14.28"}, {"groupId": "OG006", "value": "135385.91", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 12.21"}, {"groupId": "OG007", "value": "161073.09", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 4.99"}]}]}, {"title": "(AUC last)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46750.66", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 21.87"}, {"groupId": "OG001", "value": "89216.40", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 28.49"}, {"groupId": "OG002", "value": "182804.71", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG003", "value": "104060.46", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "106987.30", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 3.02"}, {"groupId": "OG005", "value": "188544.49", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 16.28"}]}]}, {"title": "(AUC(0-\u221e))", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "0"}, {"groupId": "OG009", "value": "0"}, {"groupId": "OG010", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "52467.20", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 24.00"}, {"groupId": "OG001", "value": "99576.37", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 29.22"}, {"groupId": "OG002", "value": "234888.37", "spread": "NA", "comment": "Coefficient of variation was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "126374.56", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 16.01"}, {"groupId": "OG005", "value": "211928.81", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 16.99"}, {"groupId": "OG006", "value": "187776.56", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 23.32"}, {"groupId": "OG007", "value": "225087.02", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 28.27"}]}]}]}, {"type": "SECONDARY", "title": "Apparent First-order Terminal Elimination Half-life (t1/2)", "description": "Apparent first-order terminal elimination half-life (t1/2).", "populationDescription": "All participants that received Danicamtiv with plasma concertation data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose", "groups": [{"id": "OG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C"}, {"id": "OG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D"}, {"id": "OG002", "title": "SAD Cohort 1 Danicamtiv 450mg", "description": "Participants received split dose of Danicamtiv 450mg in period D"}, {"id": "OG003", "title": "SAD Cohort 1 Danicamtiv 350mg Period D", "description": "Participants received single dose of Danicamtiv 350mg in period D"}, {"id": "OG004", "title": "SAD Cohort 1 Danicamtiv 525mg", "description": "Participants received single dose of Danicamtiv 525mg in period D"}, {"id": "OG005", "title": "SAD Cohort 1 Danicamtiv 550mg", "description": "Participants received split dose of Danicamtiv 550mg in period D"}, {"id": "OG006", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg"}, {"id": "OG007", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg"}, {"id": "OG008", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG009", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG010", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "2"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "4"}, {"groupId": "OG007", "value": "4"}, {"groupId": "OG008", "value": "8"}, {"groupId": "OG009", "value": "13"}, {"groupId": "OG010", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.96", "spread": "4.40"}, {"groupId": "OG001", "value": "20.95", "spread": "3.23"}, {"groupId": "OG002", "value": "30.62", "spread": "NA", "comment": "SD was not calculated because of insufficient number of events"}, {"groupId": "OG004", "value": "24.73", "spread": "10.76"}, {"groupId": "OG005", "value": "21.45", "spread": "0.30"}, {"groupId": "OG006", "value": "24.45", "spread": "11.363"}, {"groupId": "OG007", "value": "24.30", "spread": "13.987"}, {"groupId": "OG008", "value": "24.466", "spread": "5.8911"}, {"groupId": "OG009", "value": "20.573", "spread": "6.1033"}, {"groupId": "OG010", "value": "23.319", "spread": "3.5903"}]}]}]}, {"type": "SECONDARY", "title": "Danicamtiv Accumulation Ratio for Maximum Observed Plasma Concentration AR(Cmax) - MAD Cohorts", "description": "Accumulation ratio for maximum observed plasma concentration AR(Cmax) for Danicamtiv. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "populationDescription": "All participants in MAD Cohorts that received Danicamtiv with plasma concertation data", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose", "groups": [{"id": "OG000", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG001", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG002", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.451", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 28.0"}, {"groupId": "OG001", "value": "3.241", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 30.2"}, {"groupId": "OG002", "value": "3.827", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 20.6"}]}]}]}, {"type": "SECONDARY", "title": "Accumulation Ratio for Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours AR(AUC(0-12)) - MAD Cohorts", "description": "Accumulation ratio for area under the plasma concentration-time curve from time 0 to 12 hours AR(AUC(0-12)) for Danicamtiv. Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported.", "populationDescription": "All participants in MAD Cohorts that received Danicamtiv with plasma concertation data", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hr x ng/mL", "timeFrame": "1 hour pre-dose and day 1-12 at 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, and 48 hours postdose", "groups": [{"id": "OG000", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge"}, {"id": "OG001", "title": "MAD Cohort 1+3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}, {"id": "OG002", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.983", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 26.5"}, {"groupId": "OG001", "value": "3.696", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 36.4"}, {"groupId": "OG002", "value": "4.607", "spread": "NA", "comment": "Geometric coefficient of variation was not calculated and the arithmetic coefficient of variation (% CV) is being reported. %CV = 16.5"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 1 - SAD Cohorts", "description": "Mean change from baseline in TTE parameter systolic ejection time (SET) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to the corresponding period. Reporting arms are not mutually exclusive", "populationDescription": "All treated participants in SAD Cohorts per Danicamtiv plasma concentration ranges (Reporting arms are not mutually exclusive)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "msec", "timeFrame": "Baseline, predose and at 3, 6, 9, and 24 hours post dose", "groups": [{"id": "OG000", "title": "SAD Cohorts <2000 ng/mL", "description": "SAD Cohorts with plasma concentration less than 2000 ng/mL"}, {"id": "OG001", "title": "SAD Cohorts \u22652000 ng/mL", "description": "SAD Cohorts with plasma concentration greater than or equal to 2000 ng/mL"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.04", "spread": "10.03"}, {"groupId": "OG001", "value": "36.3", "spread": "8.2"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 2 - SAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular stroke volume (LVSV) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to the corresponding period. Reporting arms are not mutually exclusive", "populationDescription": "All treated participants in SAD Cohorts per Danicamtiv plasma concentration ranges (Reporting arms are not mutually exclusive)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL", "timeFrame": "Baseline, predose and at 3, 6, 9, and 24 hours post dose", "groups": [{"id": "OG000", "title": "SAD Cohorts <2000 ng/mL", "description": "SAD Cohorts with plasma concentration less than 2000 ng/mL"}, {"id": "OG001", "title": "SAD Cohorts \u22652000 ng/mL", "description": "SAD Cohorts with plasma concentration greater than or equal to 2000 ng/mL"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.01", "spread": "3.67"}, {"groupId": "OG001", "value": "9.01", "spread": "2.99"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 3 - SAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to the corresponding period. Reporting arms are not mutually exclusive", "populationDescription": "All treated participants in SAD Cohorts per Danicamtiv plasma concentration ranges (Reporting arms are not mutually exclusive)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of blood pumped from LV", "timeFrame": "Baseline, predose and at 3, 6, 9, and 24 hours post dose", "groups": [{"id": "OG000", "title": "SAD Cohorts <2000 ng/mL", "description": "SAD Cohorts with plasma concentration less than 2000 ng/mL"}, {"id": "OG001", "title": "SAD Cohorts \u22652000 ng/mL", "description": "SAD Cohorts with plasma concentration greater than or equal to 2000 ng/mL"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"title": "LVEF", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.06", "spread": "2.27"}, {"groupId": "OG001", "value": "4.44", "spread": "1.86"}]}]}, {"title": "LVFS", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.14", "spread": "1.36"}, {"groupId": "OG001", "value": "2.81", "spread": "1.12"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 1 - MAD Cohorts", "description": "Mean change from baseline in TTE parameter systolic ejection time (SET) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to first randomized dose. Reporting arms are not mutually exclusive", "populationDescription": "All treated participants in MAD Cohorts per Danicamtiv plasma concentration ranges (Reporting arms are not mutually exclusive)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "msec", "timeFrame": "Baseline, predose, and at 7 hours post dose on day 1,2,3, 4, 7, 9, 10, and 11", "groups": [{"id": "OG000", "title": "MAD Cohorts <2000 ng/mL", "description": "MAD Cohorts with plasma concentration less than 2000 ng/mL"}, {"id": "OG001", "title": "MAD Cohorts 2000-<3500 ng/mL", "description": "MAD Cohorts with plasma concentration between 2000 (inclusive) to 3500 (non-inclusive) ng/mL"}, {"id": "OG002", "title": "MAD Cohorts \u22653500 ng/mL", "description": "MAD Cohorts with plasma concentration greater than or equal to 3500 ng/mL"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.1", "spread": "3.51"}, {"groupId": "OG001", "value": "35.6", "spread": "3.78"}, {"groupId": "OG002", "value": "48.3", "spread": "4.68"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 2 - MAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular stroke volume (LVSV) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to first randomized dose. Reporting arms are not mutually exclusive", "populationDescription": "All treated participants in MAD Cohorts per Danicamtiv plasma concentration ranges (Reporting arms are not mutually exclusive)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL", "timeFrame": "Baseline, predose, and at 7 hours post dose on day 1,2,3, 4, 7, 9, 10, and 11", "groups": [{"id": "OG000", "title": "MAD Cohorts <2000 ng/mL", "description": "MAD Cohorts with plasma concentration less than 2000 ng/mL"}, {"id": "OG001", "title": "MAD Cohorts 2000-<3500 ng/mL", "description": "MAD Cohorts with plasma concentration between 2000 (inclusive) to 3500 (non-inclusive) ng/mL"}, {"id": "OG002", "title": "MAD Cohorts \u22653500 ng/mL", "description": "MAD Cohorts with plasma concentration greater than or equal to 3500 ng/mL"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.126", "spread": "1.8348"}, {"groupId": "OG001", "value": "7.843", "spread": "1.9511"}, {"groupId": "OG002", "value": "5.685", "spread": "2.4988"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Transthoracic Echocardiogram (TTE) Parameter 3 - MAD Cohorts", "description": "Mean change from baseline in TTE parameter left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) according to Danicamtiv plasma concentration ranges. Baseline is defined as the last non-missing value prior to first randomized dose. Reporting arms are not mutually exclusive", "populationDescription": "All treated participants in MAD Cohorts per Danicamtiv plasma concentration ranges (Reporting arms are not mutually exclusive)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of blood pumped from LV", "timeFrame": "Baseline, predose, and at 7 hours post dose on day 1,2,3, 4, 7, 9, 10, and 11", "groups": [{"id": "OG000", "title": "MAD Cohorts <2000 ng/mL", "description": "MAD Cohorts with plasma concentration less than 2000 ng/mL"}, {"id": "OG001", "title": "MAD Cohorts 2000-<3500 ng/mL", "description": "MAD Cohorts with plasma concentration between 2000 (inclusive) to 3500 (non-inclusive) ng/mL"}, {"id": "OG002", "title": "MAD Cohorts \u22653500 ng/mL", "description": "MAD Cohorts with plasma concentration greater than or equal to 3500 ng/mL"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"title": "LVEF", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "0.872"}, {"groupId": "OG001", "value": "1.12", "spread": "0.928"}, {"groupId": "OG002", "value": "2.29", "spread": "1.158"}]}]}, {"title": "LVFS", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "0.537"}, {"groupId": "OG001", "value": "0.78", "spread": "0.574"}, {"groupId": "OG002", "value": "0.51", "spread": "0.725"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3.3", "timeFrame": "Adverse Events and Serious Adverse Events were monitored from first dose to 30 days post last dose (Up to 2 months). Participants were assessed for All-cause mortality from their date of randomization to study completion (Up to approximately 20 months)", "eventGroups": [{"id": "EG000", "title": "SAD Cohort 1 Danicamtiv 175mg", "description": "Participants received single dose of Danicamtiv 175mg in either period A, B, or C", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}, {"id": "EG001", "title": "SAD Cohort 1 Danicamtiv 350mg", "description": "Participants received single dose of Danicamtiv 350mg in either period A, B, C, or D", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 5, "otherNumAtRisk": 8}, {"id": "EG002", "title": "SAD Cohort 1 Placebo", "description": "Participants received single dose of Placebo in either period A, B, or C", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}, {"id": "EG003", "title": "SAD Cohort 1 Danicamtiv Optional Period D", "description": "Participants received Danicamtiv at either 450mg, 525mg or 550mg in period D", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 1, "otherNumAtRisk": 6}, {"id": "EG004", "title": "SAD Cohort 2 Danicamtiv 400mg", "description": "Participants received split dose of Danicamtiv 400mg", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 3, "otherNumAtRisk": 4}, {"id": "EG005", "title": "SAD Cohort 2 Danicamtiv 500mg", "description": "Participants received split dose of Danicamtiv 500mg", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}, {"id": "EG006", "title": "SAD Cohort 2 Placebo", "description": "Participants received single dose of Placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 0, "otherNumAtRisk": 4}, {"id": "EG007", "title": "MAD Cohort 1 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 1, "seriousNumAtRisk": 6, "otherNumAffected": 2, "otherNumAtRisk": 6}, {"id": "EG008", "title": "MAD Cohort 1 Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 0, "otherNumAtRisk": 2}, {"id": "EG009", "title": "MAD Cohort 2 Danicamtiv 50mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 50mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 7, "otherNumAtRisk": 9}, {"id": "EG010", "title": "MAD Cohort 2 Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}, {"id": "EG011", "title": "MAD Cohort 3 Danicamtiv 75mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 75mg twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 6, "otherNumAtRisk": 9}, {"id": "EG012", "title": "MAD Cohort 3 Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}, {"id": "EG013", "title": "MAD Cohort 4 Danicamtiv 100mg", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Danicamtiv 100mg (with food) twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 5, "otherNumAtRisk": 6}, {"id": "EG014", "title": "MAD Cohort 4 Placebo", "description": "Participants received single-blinded placebo twice daily for 2 days. Participants then received double-blinded Placebo twice daily for 7 days, and 2 days of monitoring following the last dose before discharge", "deathsNumAffected": 0, "deathsNumAtRisk": 2, "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 2, "otherNumAtRisk": 2}], "seriousEvents": [{"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Cardiac discomfort", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 2, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Bowel movement irregularity", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Gingival pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Oral contusion", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Application site erosion", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Application site irritation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Application site rash", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Infusion site discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Infusion site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Vessel puncture site haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 2, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Arthropod bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Skin abrasion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Traumatic haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Electrocardiogram QRS complex prolonged", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Troponin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Fluid overload", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Hypomagnesaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Facial paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 1, "numAtRisk": 2}]}, {"term": "Testicular pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Dry throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG011", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG012", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG013", "numAffected": 0, "numAtRisk": 6}, {"groupId": "EG014", "numAffected": 0, "numAtRisk": 2}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Bristol-Myers Squibb Study Director", "organization": "Bristol-Myers Squibb", "email": "Clinical.Trials@bms.com", "phone": "Please Email"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2019-03-19", "uploadDate": "2022-10-21T21:08", "filename": "Prot_SAP_000.pdf", "size": 1506374}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-11-21", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}, {"id": "D000002311", "term": "Cardiomyopathy, Dilated"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000083083", "term": "Laminopathies"}, {"id": "D000030342", "term": "Genetic Diseases, Inborn"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M5567", "name": "Cardiomyopathy, Dilated", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M2392", "name": "Laminopathies", "relevance": "LOW"}, {"id": "M23686", "name": "Genetic Diseases, Inborn", "relevance": "LOW"}, {"id": "T1876", "name": "Dilated Cardiomyopathy", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M258342", "name": "Sulconazole", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}